Protein Variants | Comment | Organism |
---|---|---|
additional information | CRISPR/Cas9 technology is used to generate a Pf DPY19 null mutant. Pf DPY19 gene disruption is not associated with a growth phenotype, not even under endoplasmic reticulum-stressing conditions that could impair protein folding | Plasmodium falciparum |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Plasmodium falciparum | C0H4S1 | 1.2B line | - |
Source Tissue | Comment | Organism | Textmining |
---|
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
additional information | several thrombospondin type 1 repeat (TSR) domain-containing proteins of Plasmodium falciparum can be C-mannosylated in vivo | Plasmodium falciparum | ? | - |
- |
Synonyms | Comment | Organism |
---|---|---|
Dpy-19-like C-mannosyltransferase | UniProt | Plasmodium falciparum |
Pf DPY-19 | - |
Plasmodium falciparum |
PF3D7_0806200 | locus name | Plasmodium falciparum |
General Information | Comment | Organism |
---|---|---|
evolution | Plasmodium falciparum DPY19 exhibits a different acceptor specificity than the mammalian enzymes | Plasmodium falciparum |
malfunction | Pf DPY19 gene disruption is not associated with a growth phenotype, not even under endoplasmic reticulum-stressing conditions that could impair protein folding | Plasmodium falciparum |
physiological function | Plasmodium falciparum C-mannosyltransferase (Pf DPY-19) is demonstrated to modify thrombospondin type 1 repeat (TSR) domains in vitro, exhibiting a different acceptor specificity than their mammalian counterparts. The Plasmodium falciparum C-mannosyltransferase is dispensable for parasite asexual blood stage development | Plasmodium falciparum |